Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2020-10-19 Director's Dealing
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-10-19 English
PRIMARY DOCUMENT
Director's Dealing
2020-10-19 English
PRIMARY DOCUMENT
Director's Dealing
2020-10-19 English
PRIMARY DOCUMENT
Director's Dealing
2020-10-19 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 14, 2020, for Landec Corporation. It reports multiple corporate governance and management events: retirement of a director, appointment of a chairman, committee appointments, approval of bylaws amendment, and voting results from the Annual Meeting of Stockholders. It includes detailed voting results and descriptions of board and committee changes. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The primary content relates to changes in the board of directors and management structure, as well as shareholder voting outcomes. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (9064 characters) and content confirm it is not a brief announcement or a report publication notice, but a substantive filing about management and board changes.
2020-10-19 English
PRIMARY DOCUMENT
Director's Dealing
2020-10-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.